-+ 0.00%
-+ 0.00%
-+ 0.00%

PARABILIS MEDICINES ANNOUNCES OVERSUBSCRIBED $305 MILLION FINANCING TO SUPPORT ONGOING FOG-001 (ZOLUCATETIDE) CLINICAL DEVELOPMENT ACROSS A BROAD RANGE OF TUMORS AND ADVANCE PIONEERING PIPELINE AND HELICON PLATFORM

Reuters·01/08/2026 12:03:00

Please log in to view news